Computer-aided drug discovery

Aurlide is a Finnish service provider in computer-aided drug discovery. We help companies speed up and de-risk preclinical development by providing proprietary technology and expertise in hit identification and hit-to-lead/lead optimization. We typically generate multiple potent hit series with excellent developability profiles - one of the most important ways of early de-risking of preclinical development.

Aurlide has an in-house computational platform for the design of cyclic peptides i.e. macrocycles. The platform has already delivered >50 experimentally confirmed binders to targets spanning from hard-to-drug PPIs to kinases. Our macrocycle designs achieve high binding affinity to challenging PPIs while retaining small molecule-like ADME/PK profile, enabling the targeting of intracellular PPIs.

As recent highlights, our virtual drug discovery platform has enabled partners to advance an in silico hit to a preclinical candidate in 15 months. Recently, we identified a novel lead series for a challenging ion channel target for a client (patent WO2025017103).